Mark J Koruda
Overview
Explore the profile of Mark J Koruda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toyonaga T, Araba K, Kennedy M, Keith B, Wolber E, Beasley C, et al.
bioRxiv
. 2020 Dec;
PMID: 33269348
Background And Aims: The host receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), is highly expressed in small intestine. Our aim was to study colonic ACE2 expression in Crohn's disease (CD)...
2.
Toyonaga T, Steinbach E, Keith B, Barrow J, Schaner M, Wolber E, et al.
Cell Mol Gastroenterol Hepatol
. 2020 Jun;
10(4):779-796.
PMID: 32561494
Background & Aims: Intestinal epithelial cell (IEC) barrier dysfunction is critical to the development of Crohn's disease (CD). However, the mechanism is understudied. We recently reported increased microRNA-31-5p (miR-31-5p) expression...
3.
Shahir N, Wang J, Wolber E, Schaner M, Frank D, Ir D, et al.
Inflamm Bowel Dis
. 2020 May;
26(12):1843-1855.
PMID: 32469069
Background: The intestinal microbiota play a key role in the onset, progression, and recurrence of Crohn disease (CD). Most microbiome studies assay fecal material, which does not provide region-specific information...
4.
Strassle P, Kinlaw A, Chaumont N, Angle H, Lumpkin S, Koruda M, et al.
Gastroenterology
. 2019 Sep;
157(6):1679-1681.e11.
PMID: 31499038
No abstract available.
5.
Keith B, Barrow J, Toyonaga T, Kazgan N, Hoffner OConnor M, Shah N, et al.
JCI Insight
. 2018 Oct;
3(19).
PMID: 30282822
Background: Crohn's disease (CD) is highly heterogeneous, due in large part to variability in cellular processes that underlie the natural history of CD, thereby confounding effective therapy. There is a...
6.
Weiser M, Simon J, Kochar B, Tovar A, Israel J, Robinson A, et al.
Gut
. 2016 Oct;
67(1):36-42.
PMID: 27742763
Objective: The clinical presentation and course of Crohn's disease (CD) is highly variable. We sought to better understand the cellular and molecular mechanisms that guide this heterogeneity, and characterise the...
7.
Simon J, Davis J, Lee S, Schaner M, Gipson G, Weiser M, et al.
Eur J Immunol
. 2016 May;
46(8):1912-25.
PMID: 27159132
Intestinal macrophages (IMs) are uniquely programmed to tolerate exposure to bacteria without mounting potent inflammatory responses. The cytokine IL-10 maintains the macrophage anti-inflammatory response such that loss of IL-10 results...
8.
Dehmer J, Stafford R, Marshall H, Koruda M, Meyer A
Am Surg
. 2011 Sep;
77(7):960-1.
PMID: 21944367
No abstract available.
9.
Koruda M
J Gastrointest Surg
. 2008 Dec;
13(3):401-2.
PMID: 19082667
Temporary diverting ileostomies are routine performed as a "protective" adjunct to ileal pouch procedures. The need for routine diverting ileostomies has been challenged because of the risks associated with their...
10.
Cohen Z, Senagore A, Dayton M, Koruda M, Beck D, Wolff B, et al.
Dis Colon Rectum
. 2005 May;
48(6):1130-9.
PMID: 15868230
Introduction: Postoperative abdominal adhesions are associated with significant morbidity and mortality, placing a substantial burden on healthcare systems worldwide. Development of a bioresorbable membrane containing up to 23 percent glycerol...